Symbols

PLRX

Pliant Therapeutics·NASDAQ

--(--)

PLRX Profile

Pliant Therapeutics, Inc.

A clinical stage biopharmaceutical company that developing novel therapies for fibrosis and related diseases

Industry

Pharmaceutical

Established Date

Listing Date

06/03/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.pliantrx.com

Security Type

Common stock

Office address

331 Oyster Point Boulevard South San Francisco CA 94080

Business

Introduction

Pliant Therapeutics, Inc., incorporated under the laws of the State of Delaware in June 2015, is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapies. The company's main project is dedicated to the development of solid tumor treatments by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β). With a deep understanding of integrin biology and expertise in medicinal chemistry and translational medicine, Pliant has developed a proprietary drug discovery platform for a variety of disease areas. The Company's lead product candidate, PLN-101095, is an oral small molecule drug designed to inhibit αvβ8 and αvβ1 integrins for the treatment of solid tumors. Pliant will continue to research its drug discovery platform, which includes a proprietary integrin-binding molecular library designed to enable targeted drug delivery.